MIT Biotechnology Group

Navigating Uncharted Waters: Clinical Strategy Amid Rapid Innovation

Scientific innovation is crucial to the biopharma industry, but also presents key challenges for clinical development. A clinical program takes several years to complete, after which point the standards of care may have changed dramatically. The impact that immunotherapy has had in melanoma and lung cancer exemplifies this issue. As the pace of innovation accelerates, the challenges grow more acute.

During this seminar, Dennis Chang, a Principal at Clarion Healthcare, will discuss approaches to anticipating and adapting to continuing innovations in the field of oncology, including approaches for predicting the impact of new mechanisms on cancer treatment and the founding of a new collaborative paradigm for testing combination therapies.

About Post Author

About Us

The MIT Biotechnology Group was founded to increase the pace of innovation by training student leaders in the biotechnology space. We are committed to building a community that strengthens the relationship between students and Boston’s biotechnology community.